Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 91,707 shares of the biopharmaceutical company's stock after selling 6,104 shares during the quarter. New York State Teachers Retirement System owned approximately 0.08% of Regeneron Pharmaceuticals worth $58,163,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of REGN. Amalgamated Bank increased its stake in Regeneron Pharmaceuticals by 1.2% in the first quarter. Amalgamated Bank now owns 20,620 shares of the biopharmaceutical company's stock valued at $13,078,000 after purchasing an additional 247 shares during the last quarter. Essex Financial Services Inc. increased its stake in shares of Regeneron Pharmaceuticals by 23.5% during the 1st quarter. Essex Financial Services Inc. now owns 410 shares of the biopharmaceutical company's stock valued at $260,000 after acquiring an additional 78 shares during the last quarter. KBC Group NV increased its stake in shares of Regeneron Pharmaceuticals by 9.4% during the 1st quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after acquiring an additional 12,793 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 0.3% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 303,669 shares of the biopharmaceutical company's stock worth $192,596,000 after acquiring an additional 1,053 shares during the period. Finally, 3Chopt Investment Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $259,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Down 0.5%

Shares of REGN stock traded down $2.74 during mid-day trading on Friday, reaching $545.00. 456,413 shares of the company were exchanged, compared to its average volume of 905,431. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The business's 50 day simple moving average is $550.54 and its 200 day simple moving average is $627.29. The company has a market capitalization of $58.84 billion, a P/E ratio of 13.87, a P/E/G ratio of 2.00 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company's revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the company earned $9.55 earnings per share. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on REGN shares. JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research note on Monday, June 9th. Royal Bank Of Canada downgraded Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective for the company. in a report on Friday, May 30th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Bank of America lowered their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research report on Thursday, April 17th. Finally, BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a report on Monday, June 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $822.58.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.